1990~2017年中国膀胱癌疾病负担分析  

An analysis of disease burden of bladder cancer in China from 1990 to 2017

作　　者：訾豪 彭谋 王江宜[4] 胡海亮 杨璐 姚海军[7] 陈征 周靖程 郭佳 徐晓峰[12] 罗丽莎 李晓东 孙中义[14] 翁鸿 曾涛 曾宪涛[1,15,17] Hao ZI;Mou PENG;Jiang-Yi WANG;Hai-Liang HU;Lu YANG;Hai-Jun YAO;Zheng CHEN;Jing-Cheng ZHOU;Jia GUO;Xiao-Feng XU;Li-Sha LUO;Xiao-Dong LI;Zhong-Yi SUN;Hong WENG;Tao ZENG;Xian-Tao ZENG(Center for Evidence-Based and Translational Medicine,Zhongnan Hospital of Wuhan University,Wuhan 430071,China;Department of Microbiology and Immunology,Albert Einstein College of Medicine,Bronx,NY 10461,USA;Department of Urology,The Second Xiangya Hospital of Central South University,Changsha 410011,China;Department of Urology,Fudan University Shanghai Cancer Center,Shanghai 200032,China;Department of Pathology,Duke University School of Medicine,Durham,NC 27710,USA;Department of Urology,West China Hospital of Sichuan University,Chengdu 610041,Chin;a 7.Department of Urology,Shanghai Ninth People's Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200011,China;Department of Urology,Third Affiliated Hospital,Sun Yat-Sen University,Guangzhou 510630,China;Department of Urology,Peking University First Hospital,Beijing 100034,China;Institute of Urology,Peking University,Beijing 100034,China;Department of Urology,Renmin Hospital of Wuhan University,Wuhan 430060,China;Department of Urology,Xianyang Central Hospital,Xianyang 712000,Shaanxi Province,China;Institute of Evidence-Based Medicine and Knowledge Translation,Henan University,Kaifeng 475000,Henan Province,China;Department of Urology,Shenzhen Hospital,Peking University,Shenzhen 518036,Guangdong Province,China;Department of Urology,Zhongnan Hospital of Wuhan University,Wuhan 430071,China;Department of Urology,Jiangxi Provincial People's Hospital Affiliated to Nanchang University,Nanchang 330006,China;Division of Personnel Services,Zhongnan Hospital of Wuhan University,Wuhan 430071,China)

机构地区：[1]武汉大学中南医院循证与转化医学中心,武汉430071 [2]美国艾伯特爱因斯坦医学院微生物与免疫学系,纽约州布朗克斯10461 [3]中南大学湘雅第二医院泌尿外科,长沙410011 [4]复旦大学附属肿瘤医院泌尿外科,上海200032 [5]美国杜克大学医学院病理系,北卡罗来纳州达勒姆27710 [6]四川大学华西医院泌尿外科,成都610041 [7]上海交通大学第九人民医院泌尿外科,上海200011 [8]中山大学第三医院泌尿外科,广州510630 [9]北京大学第一医院泌尿外科,北京100034 [10]北京大学泌尿外科研究所,北京100034 [11]武汉大学人民医院泌尿外科,武汉430060 [12]咸阳市中心医院泌尿外科,陕西咸阳712000 [13]河南大学循证医学与临床转化研究院,河南开封475000 [14]北京大学深圳医院泌尿外科,广东深圳518036 [15]武汉大学中南医院泌尿外科,武汉430071 [16]江西省人民医院泌尿外科,南昌330006 [17]武汉大学中南医院人事处,武汉430071

出　　处：《医学新知》2020年第5期328-335,共8页New Medicine

基　　金：科技部国家国际合作专项项目(SQS2014RR125);国家自然科学基金面上项目(81772730);国家自然科学基金地区项目(81860455);湖北省技术创新专项(2018ACA159);江西省科技厅课题(20161BBG70130);湖南省自然科学基金青年项目(2018JJ3762)。

摘　　要：目的分析1990~2017年中国膀胱癌疾病负担的变化趋势。方法利用2017年全球疾病负担研究结果,采用膀胱癌发病率、死亡率、伤残调整寿命年(Disability-adjusted life year,DALY)、过早死亡损失寿命年(Years of life lost,YLL)、伤残损失寿命年(Years lived with disability,YLD)及其标化率对1990年和2017年间中国人群膀胱癌疾病负担情况进行描述。结果2017年中国膀胱癌发病例数为7.30万,标化发病率为3.89/10万,死亡例数为3.06万,标化死亡率为1.75/10万。与1990年相比,发病例数增加了164.49%,标化发病率增加了15.09%,死亡例数增加了92.45%,标化死亡率降低了23.58%。男性的发病率和死亡率要高于女性,并且随年龄的增加呈现上升趋势。相比1990年,2017年我国膀胱癌的DALY标化率降低了26.35%,YLL标化率降低了28.59%,YLD标化率增加了28.83%。1990~2017年,我国膀胱癌DALY率整体呈下降趋势,但男性DALY率仍高于女性。结论1990~2017年我国膀胱癌的标化发病率不断上升,标化死亡率呈下降趋势,男性和老年人群是膀胱癌疾病负担的高危人群。Objective To analyze the trend of disease burden of bladder cancer in China from 1990 to 2017.Methods Data were obtained from the results of Global Burden of Disease Study 2017(GBD 2017).Bladder cancer incidence,mortality,disability-adjusted life year(DALY),years of life lost(YLL),and years lived with disability(YLD)were used to describe the changes of disease burden of bladder cancer in Chinese population between 1990 and 2017.The incidence,mortality,DALY rate,YLL rate,and YLD rate were standardized by the Global Burden of Disease(GBD)global standard population in 2017.Results In 2017,the number of new cases of bladder cancer in China was 73,000 with the standardized incidence rate of 3.89/100,000 and the number of deaths was 30,600 with the standardized mortality rate of 1.75/100,000.Compared to 1990,the number of new cases increased by 164.49%accompanying with the increased incidence rate by 15.09%and the number of deaths increased by 92.45%but accompanying with the decreased standardized mortality rate by 23.58%.Furthermore,male’s incidence and mortality were higher than that of female and showed an upward trend with aging.Compared to 1990,the standardized DALY rate and standardized YLL rate of bladder cancer in China in 2017 decreased by 26.35%and 28.59%,respectively,and the standardized YLD rate increased by 28.83%.From 1990 to 2017,the DALY rate of bladder cancer in China showed a downward trend,but the DALY rate of male was still higher than that of female.Conclusions From 1990 to 2017,the standardized incidence rate of bladder cancer in China continued to rise,and the standardized mortality rate showed a downward trend.Male and elder population was the high-risk population for bladder cancer.

关 键 词：膀胱癌 发病率 死亡率 疾病负担 伤残调整寿命年 

分 类 号：R737.14[医药卫生—肿瘤]